

P A T E N T S

CESION

El (los) suscrito (s)

1. Dongxu SHU
2. Pengcheng Patrick SHAO
3. Shiwei XIA

en consideración al pago de la suma de 1 USD, que he(mos) recibido, por el presente documento cedo (cedemos) a

SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.

una compañía constituida de conformidad con las leyes de China

con oficinas en **J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town Jiading District, Shanghai 201803, CN**

todos los derechos y títulos sobre la invención denominada

Entrada en fase nacional de PCT/CN2024/123536 con fecha 09.10.2024
Reivindicando prioridad de PCT/CN2023/123698 con fecha 10.10.2023 y de PCT/CN2023/136289 con fecha 05.12.2023

EL CESIONARIO firma también el presente y declara que acepta dicha cesión

Dado y firmado hoy

en

ASSIGNMENT

The undersigned

1. Dongxu SHU
2. Pengcheng Patrick SHAO
3. Shiwei XIA

in consideration of the sum of 1 USD, the receipt of which is hereby acknowledged, by these presents do sell, assign and transfer unto

SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.

a corporation organized under the laws of China

having a place of business at **J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town Jiading District, Shanghai 201803, CN**

all rights and title to the invention related to
COMPOSITIONS AND METHODS FOR INHIBITING
EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP)

Entry into national phase of PCT/CN2024/123536 dated 09.10.2024

Claiming priority from PCT/CN2023/123698 dated 10.10.2023 and from PCT/CN2023/136289 dated 05.12.2023

THE ASSIGNEE signs these presents and declares that accepts the aforesaid assignment

Given and signed this March 20, 2026

in Beijing, China



Dongxu SHU

Signature of the Assignor
(Firma del cedente)

025-0001.

P A T E N T S

Pengcheng Patrick SHAO

Signature of the Assignor
(Firma del cedente)

Shiwei Xia

Shiwei XIA

Signature of the Assignor
(Firma del cedente)

Dongxu Shu

Dongxu SHU, CEO

Signature of the Assignee
(Firma del cesionario)

黄瑞 →

P A T E N T S

CESION

El (los) suscrito (s)

1. Dongxu SHU
2. Pengcheng Patrick SHAO
3. Shiwei XIA

en consideración al pago de la suma de 1 USD, que he(mos) recibido, por el presente documento cedo (cedemos) a

SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.

una compañía constituida de conformidad con las leyes de China

con oficinas en J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town Jiading District, Shanghai 201803, CN


todos los derechos y títulos sobre la invención denominada

Entrada en fase nacional de PCT/CN2024/123536 con fecha 09.10.2024
Reivindicando prioridad de PCT/CN2023/123698 con fecha 10.10.2023 y de PCT/CN2023/136289 con fecha 05.12.2023

EL CESIONARIO firma también el presente y declara que acepta dicha cesión

Dado y firmado hoy

en



Dongxu SHU
Signature of the Assignor
(Firma del cedente)

ASSIGNMENT

The undersigned

1. Dongxu SHU
2. Pengcheng Patrick SHAO
3. Shiwei XIA

in consideration of the sum of 1 USD, the receipt of which is hereby acknowledged, by these presents do sell, assign and transfer unto

SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.

a corporation organized under the laws of China

having a place of business at J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town Jiading District, Shanghai 201803, CN

all rights and title to the invention related to
COMPOSITIONS AND METHODS FOR INHIBITING
EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP)

Entry into national phase of PCT/CN2024/123536 dated 09.10.2024

Claiming priority from PCT/CN2023/123698 dated 10.10.2023 and from PCT/CN2023/136289 dated 05.12.2023

THE ASSIGNEE signs these presents and declares that accepts the aforesaid assignment

Given and signed this March 20, 2026

in Shanghai, China

P A T E N T S

Pengcheng Patrick Shao

Pengcheng Patrick SHAO

Signature of the Assignor
(Firma del cedente)

Shiwei XIA

Signature of the Assignor
(Firma del cedente)

Dongxu Shu

DONGXU SHU; CEO

Signature of the Assignee
(Firma del cesionario)